The Mannedrol, or levonorgestrel intrauterine device system, is a new type of intrauterine device with a T-ring plastic stent that does not have a radical cure for adenomyosis. However, as a conservative treatment modality for the disease, it helps to improve the clinical symptoms of adenomyosis. It usually provides stable efficacy for 5 years and has the effect of regulating progesterone and estrogen levels, reducing menstrual flow, relieving dysmenorrhea, inhibiting inflammatory factor secretion, endothelial cell proliferation, and regulating endothelial coagulation. Adenomyosis occurs in menstruating women and is usually characterized by nodules or masses in the uterus, which may cause pain and infertility. When a patient initially uses the levonorgestrel IUD system, degenerative changes in the endometrial vessels may occur, helping to reduce menstrual flow. However, symptoms of spotting bleeding, dysmenorrhea, and increased menstrual flow may be present during initial use and are normal reactions, which usually resolve within 3-6 months. Often, improvement in menstrual pain and increased menstrual flow may occur 1-3 months after placement of the uterine cavity. In addition, surgery is the best way to cure adenomyosis. Patients are advised to choose traditional hysterectomy, laparoscopic total hysterectomy or subtotal hysterectomy, laparoscopic uterine artery blocking, and high-intensity focused ultrasound ablation under the guidance of a professional doctor according to the situation, but it usually causes more damage to the patient’s organism and may have certain effects on ovarian function.